Damora Therapeutics, Inc. (DMRA) Form 10-Q — Aug 10, 2026

$DMRAForm 10-QFiled Aug 10, 2026, 4:00 PM ET0001193125-26-342307Original filing

Damora Therapeutics (DMRA) reported a Q2 2026 net loss of $31.2 million ($0.39 per share), up from $3.4 million a year ago, as R&D spending ramped to $25.5 million and G&A to $9.5 million following its November 2025 asset acquisition of Pre-Acquisition Damora (formerly Galecto, Inc.). H1 2026 net loss totaled $59.0 million with operating cash burn of $42.5 million. The balance sheet is heavily funded: cash more than doubled to $540.5 million, boosted by a $285 million PIPE, a $295.5 million follow-on at $19.00 per share, and $29.3 million in ATM sales at $24.16. Management states existing cash funds operations for at least one year, with $120.0 million of ATM capacity still available.

Key figures

Revenue: None - the Company has not generated revenue; no products approved
Net Income: -$31.2 million net loss for Q2 2026 (-$59.0 million for H1 2026)
Total Debt: No debt disclosed; total liabilities of $27.6 million
Total Assets: 543636000
Cash Position: 540515000
Shares Outstanding: 61735519
Ga Expense Q2 2026: $9.5 million (vs $2.0 million in Q2 2025)
Rd Expense Q2 2026: $25.5 million (vs $1.5 million in Q2 2025)
Accumulated Deficit: $546.3 million
Atm Remaining Capacity: $120.0 million under $150.0 million ATM program
Nov2025 Pipe Gross Proceeds: $285 million (39,641 Series C shares at ~$7,186.90/share; $267.0 million net)
Operating Cash Burn H1 2026: -$42.5 million (vs -$4.7 million in H1 2025)
Feb2026 Follow On Net Proceeds: $295.5 million (16,644,737 shares at $19.00)
Paragon Milestones Per Product: up to $22.0 million; $2.5 million expected on first Phase 1 dosing
Estimated Us Addressable Market: $5 billion for mutCALR-driven ET and MF

Price after filing

1 day: 0.0%7 days: +3.9%30 days: -2.5%

Close on the filing date to close N calendar days later (from $29.92). Historical, not a forecast.

AI analysis

Red flags7 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.